MedTrace Logo

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

NCT02005744 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-07-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.

Conditions

  • Liver Dysfunction

Interventions

DRUG

CKD-501

CKD-501 0.5mg, PO(per oral), once

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min Soo Park, Ph.D. M.D · Severance Hospital

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005744 on ClinicalTrials.gov